S. Iapichino, A. Colzi, V. Massimo - Vol. 6, Marzo 2000, num.1
The withdrawal syndrome is well described for Tricyclic Antidepressant TCA and MonoAminoOxidase Inhibitors IMAO (Tyrer, 1984) and as been attributed to the cholinergic rebound (Dilsaver & Greden, 1983). Yet the newer Selective Serotonin Reuptake Inhibitor (SSRIs) may cause physical and psychological symptoms after acute discontinuation (Szabadi, 1992; Louie and Coll., 1994; Koopowitz & Berk, 1995). Some of the symptoms described after SSRIs to those reported with TCA withdrawal. The incidence of discontinuation symptoms varies widely among the different pharmacokinetic and pharmacodynamic profiles of the SSRIs.